BELLUS Health Inc - Strategy, SWOT and Corporate Finance Report

BELLUS Health Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company

Key Highlights

BELLUS Health Inc (BELLUS Health) is a clinical-stage biopharmaceutical company that focuses on developing novel threapetuics for treating patients with chronic cough and hypersensitization-related disorders. The company’s lead product, BLU-593 (formerly NEO5937) is a potent, orally bio-available, highly selective small molecule antagonist of the P2X3 receptor which is being developed for treating chronic cough. It has license agreement and collaborations with NEOMED institute and Parteq for the development and commercialization of BLU-593. BELLUS Health has completed the Phase I trials of BLU-593 and is planning to initiate a Phase II study in patients suffering with refractory unexplained chronic cough. BELLUS Health is headquartered in Laval, Quebec, Canada.

Scope

  • Detailed information on BELLUS Health Inc required for business and competitor intelligence needs
  • A study of the major internal and external factors affecting BELLUS Health Inc in the form of a SWOT analysis
  • An in-depth view of the business model of BELLUS Health Inc including a breakdown and examination of key business segments
  • News about BELLUS Health Inc, such as business expansion, restructuring, and contract wins
  • Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

  • Gain understanding of BELLUS Health Inc and the factors that influence its strategies.
  • Track strategic initiatives of the company and latest corporate news and actions.
  • Assess BELLUS Health Inc as a prospective partner, vendor or supplier.
  • Support sales activities by understanding your customers' businesses better.
  • Stay up to date on BELLUS Health Incs business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

Univalor Inc

Proclara Biosciences Inc

Pfizer Inc

Genzyme Corp

FoldRx Pharmaceuticals Inc

Univalor Inc

Proclara Biosciences Inc

Pfizer Inc

Genzyme Corp

FoldRx Pharmaceuticals Inc

Table of Contents

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

BELLUS Health Inc - Key Facts

BELLUS ...

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

BELLUS Health Inc - Key Facts

BELLUS Health Inc - Key Employees

BELLUS Health Inc - Key Employee Biographies

BELLUS Health Inc - Major Products and Services

BELLUS Health Inc - History

BELLUS Health Inc - Company Statement

BELLUS Health Inc - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 – Company Analysis

Company Overview

BELLUS Health Inc - Business Description

BELLUS Health Inc - SWOT Analysis

SWOT Analysis - Overview

BELLUS Health Inc - Strengths

BELLUS Health Inc - Weaknesses

BELLUS Health Inc - Opportunities

BELLUS Health Inc - Threats

BELLUS Health Inc - Key Competitors

Section 3 – Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances

BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

BELLUS Health Inc, Recent Deals Summary

Section 5 – Company’s Recent Developments

May 08, 2019: BELLUS Health reports financial and operating results for the first quarter ended march 31, 2019

Feb 21, 2019: BELLUS Health presents 2018 highlights and 2019 corporate plan

Aug 08, 2018: BELLUS Health reports financial and operating results for the second quarter ended june 30, 2018

May 15, 2018: BELLUS Health Announces Financial Results for the First Quarter Ended March 31, 2018

Feb 21, 2018: BELLUS Health Reports Financial and Operating Results for the Year Ended December 31, 2017

Jan 09, 2018: BELLUS Health Receives Milestone Payment from Taro Pharmaceuticals

Section 6 – Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List of Tables

List of Tables

BELLUS Health Inc, Key Facts

BELLUS Health Inc, Key Employees

BELLUS Health Inc, Key Employee Biographies

BELLUS Health Inc, Major Products and ...

List of Tables

BELLUS Health Inc, Key Facts

BELLUS Health Inc, Key Employees

BELLUS Health Inc, Key Employee Biographies

BELLUS Health Inc, Major Products and Services

BELLUS Health Inc, History

BELLUS Health Inc, Subsidiaries

BELLUS Health Inc, Key Competitors

BELLUS Health Inc, Ratios based on current share price

BELLUS Health Inc, Annual Ratios

BELLUS Health Inc, Annual Ratios (Cont...1)

BELLUS Health Inc, Interim Ratios

BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

BELLUS Health Inc, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List of Figures

List of Figures

BELLUS Health Inc, Performance Chart (2014 - 2018)

BELLUS Health Inc, Ratio Charts

BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Year, ...

List of Figures

BELLUS Health Inc, Performance Chart (2014 - 2018)

BELLUS Health Inc, Ratio Charts

BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@marketline.com
+44 (0) 161 359 5817

Saved reports